论文部分内容阅读
目的:观察黄连素联合培菲康治疗腹泻型肠易激惹综合征的疗效和安全性。方法:将90例腹泻型肠易激惹综合征患者分为三组,每组病例均30例。联合治疗组为黄连素联合培菲康治疗组;对照组两组为单用培菲康组和单用黄连素组。治疗2周后三组进行疗效比较。结果:联合治疗组总有效率93.3%,单用黄连素组总有效率66.7%,单用培菲康组总有效率70.0%,联合治疗组总有效率明显优于各单用药物对照组(P<0.05),单用黄连素组与单用培菲康组比较,总有效率差异无显著性(P>0.05)。三组患者均未发现明显的不良反应。结论:黄连素联合培菲康治疗腹泻型肠易激综合征安全、有效,值得临床推广使用。
Objective: To observe the efficacy and safety of berberine combined with Peifukang in treating diarrhea-predominant irritable bowel syndrome. Methods: 90 cases of diarrhea-predominant irritable bowel syndrome patients were divided into three groups, each group of 30 cases. The combined treatment group was berberine combined with Peifukang treatment group; the control group, the two groups were single Peifukang group and single berberine group. Three weeks after treatment, the three groups were compared. Results: The total effective rate was 93.3% in the combination therapy group, 66.7% in the berberine alone group, and 70.0% in the combined therapy group. The total effective rate in the combination therapy group was significantly better than that in the single drug therapy group P <0.05). There was no significant difference in the total effective rate between the berberine group and the single Peifeikang group (P> 0.05). No significant adverse reactions were found in the three groups of patients. Conclusion: Berberine combined with Peifukang in the treatment of diarrhea-predominant irritable bowel syndrome is safe and effective and is worthy of clinical promotion.